ADVISORY, March 11, 2013 (GLOBE NEWSWIRE) -- What: KaloBios Pharmaceuticals, Inc. [KBIO], a biopharmaceutical company dedicated to improving the lives of seriously ill patients with difficult-to-treat diseases through a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs), will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, David Pritchard, President & CEO, will ring the Closing Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Tuesday, March 12, 2013 – 3:45 p.m. to 4:00 p.m. ET Contact : Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210 Joan@Kureczka-Martin.com Consuelo Alatorre KaloBios Pharmaceuticals, Inc. Tel: (650) 243-3120 Mobile: (650) 278-6805 email@example.com NASDAQ MarketSite: Jen Knapp (212) 401-8916 Jennifer.firstname.lastname@example.org Feed Information: Fiber Line (Encompass Waterfront): 4463
|Gal 3C/06C 95.05 degrees West|
|18 mhz Lower|
|DL 3811 Vertical|
Currently, KaloBios has three drug development programs:
- KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma and is currently enrolling patients in a 150 patient Phase 2 study in the United States, Europe and Australia.
- KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pseudomonas aeruginosa ( Pa) infection. KaloBios has retained rights for the cystic fibrosis (CF) indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa infection in the United States. Sanofi is pursuing a ventilator associated pneumonia prevention indication in the intensive care setting.
- KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.